Filter Results
20 results
- Data for: Neurological Complications of COVID-19 Predict Worse Outcomes During HospitalizationFull, Clean data cleared by IRB and completely de-identified.
- Dataset
- Data for: 5-Aminolevulinic Acid for Recurrent Malignant Gliomas: a Systematic ReviewSupplementary materials associated with the following article: "5-Aminolevulinic Acid for Recurrent Malignant Gliomas: a Systematic Review (Broekx. S et al.)".
- Dataset
- Data for: A novel bone cement screw system combined with vertebroplasty for the treatment of Kummell disease with bone deficiency at vertebral anterior border: minimum 3-year follow-up studybrief data
- Dataset
- Data for: Cervical disc degeneration reduces distance between vertebral artery and surgical landmarksDisc degeneration and distance from the uncinate process to the vertebral artery.
- Dataset
- Data for: Safety and efficacy of polyetheretherketone (PEEK) cages in combination with one-stage posterior debridement and instrumentation in Lumbar Brucella SpondylitisThe aim of this study was to explore the efficacy and safety of surgical treatment of lumbar brucella spondylitis with PEEK cages combined with one-stage posterior debridement and instrumentation.
- Dataset
- Data for: Transradial Access for Thrombectomy in Acute Stroke: A Systematic Review and Meta-AnalysisFigures demonstrating results from meta-analysis.
- Dataset
- Data for: Hemorrhagic Presentations of COVID-19: Risk factors for mortalityCOVID 19 and Cerebral hemorrhage
- Dataset
- Data for: THE RATIO OF FACIAL NERVE TO FACIAL CANAL AS AN INDICATOR OF ENTRAPMENT IN BELL'S PALSY: A STUDY BY CT AND MRISPSS data including measurements of facial nerve and facial canal by MRI and CT. Demographic data is also included.
- Dataset
- Data for: Evaluating the Utility of Fasting Lipid Panel In Addition to Random Lipid Panel In Determining Lipid-Lowering Therapy in Acute Ischemic Stroke or TIA PatientsObjective. To determine if obtaining fasting lipid levels in addition to random lipid levels prompts changes in hyperlipidemia management of acute stroke patients. Methods. 206 patients met the study criteria which included a diagnosis of acute ischemic stroke or transient ischemic attack on admission and availability of both random and fasting LDL levels collected within 72 hours of each other. The dataset was analyzed to conform to the 2018 AHA/ACC guidelines using an LDL cutoff of 70 mg/dL. Results. In 206 patients, statin management would change based on the fasting LDL level in 12 patients, 11 of whom were in Group B. Our data suggests that lipid management is more likely to change if the initial random LDL falls between 70-99 mg/dL as compared to a value outside of this range (P<0.001).
- Dataset
- Data for: TARGETING HIGHER LEVELS OF LACTATE IN THE POST-INJURY PERIOD FOLLOWING TRAUMATIC BRAIN INJURYNinety-six patients at 12 months post-injury follow-ups TBI (post-TBI) were investigated; plasma lactate and pyruvate levels were measured by the spectrophotometric method according to the manufacturer protocols. These assays were performed using standard kits (Lactate acid Abris, REF320.1.50 and Pyruvate Abris, REF333.1.50; Abrisplus, Russia). Ceruloplasmin and lactate dehydrogenase were measured in sera by enzyme-linked immunosorbent assays according to the manufacturer’s protocol using the commercially available ELISA kit (Sigma, USA) on the USA Stat Fax analyzer; the optical density was determined with a microplate reader set to 450 nm. The ceruloplasmin levels were determined by turbidimetry (Olympus AU680, Japan) at 340 nm using the assay kit (Spinreact, N1102062, Spain). Tau concentrations were measured by ELISA method using Human Tau ELISA kit (Sigma, USA) on the USA Stat Fax analyzer (Department of Clinical Biochemistry; Kharkiv National Medical University). Group 1 was comprised of 54 participants (mean age±SD 39.92±10.5 years) who had a history of mild TBI, group 2 (mean age±SD 37.36±10.2 years) was comprised of 42 patients who had a history of moderate TBI. We found the highest plasma lactate levels in the patients with the post-injury period following moderate TBI as compared to controls (p=0.0047, t=2.924, 95% CI -0.2154 to -0.04071) where the median lactate level was 0.832±0.033 and 0,704±0.021 mmol/L in controls. No significant differences were seen between mild and moderate post-TBI (p=0.079; t=1.772); significant difference was also seen between general post-TBI group versus controls (p=0.0181; t=2.396; 95% CI -0.1627 to -0.01551) with the median of total lactate level 0.793±0.019 mmol/L. Lactate data did not distinguish with the respect to gender and age. The results showed no significant differences in tau protein, pyruvate, lactate dehydrogenase and ceruloplasmin levels. We didn’t find elevated tau protein levels in the serum samples of the patients from the general clinical group as compared to controls (p=0.0897, t=1.710; 95% CI -1.27 to 18.19) and in this patient group the median of total tau level was 79.57±24.41 pg/ml and 71.14±20.56 pg/ml, in controls. Conclusion: The study shows data, revealing higher lactate levels in the post-injury period following TBI that reflect post-injury oxidative dysmetabolism and are more expressed in the post-injury period following moderate TBI.
- Dataset
1